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Purpose: The increasing diabetes prevalence and advent of new treatments for its major visual-threatening
complications (diabetic macular edema [DME] and proliferative diabetic retinopathy [PDR]), which require frequent
life-long follow-up, have increased hospital demands markedly. Subsequent delays in patient’s evaluation and
treatment are causing sight loss. Strategies to increase capacity are needed urgently. The retinopathy (EMERALD)
study tested diagnostic accuracy, acceptability, and costs of a new health care pathway for people with previ-
ously treated DME or PDR.
Design: Prospective, multicenter, case-referent, cross-sectional, diagnostic accuracy study undertaken in 13
hospitals in the United Kingdom.
Participants: Adults with type 1 or 2 diabetes previously successfully treated DME or PDR who, at the time
of enrollment, had active or inactive disease.
Methods: A new health care pathway entailing multimodal imaging (spectral-domain OCT for DME, and 7-
field Early Treatment Diabetic Retinopathy Study [ETDRS] and ultra-widefield [UWF] fundus images for PDR)
interpreted by trained nonmedical staff (ophthalmic graders) to detect reactivation of disease was compared with
the current standard care (face-to-face examination by ophthalmologists).
Main Outcome Measures: Primary outcome: sensitivity of the new pathway. Secondary outcomes: speci-
ficity; agreement between pathways; costs; acceptability; proportions requiring subsequent ophthalmologist
assessment, unable to undergo imaging, and with inadequate images or indeterminate findings.
Results: The new pathway showed sensitivity of 97% (95% confidence interval [CI], 92%e99%) and specificity
of 31% (95% CI, 23%e40%) to detect DME. For PDR, sensitivity and specificity using 7-field ETDRS images (85%
[95% CI, 77%e91%] and 48% [95% CI, 41%e56%], respectively) or UWF images (83% [95% CI, 75%e89%] and
54% [95% CI, 46%e61%], respectively) were comparable. For detection of high-risk PDR, sensitivity and specificity
were higher when using UWF images (87% [95% CI, 78%e93%] and 49% [95% CI, 42%e56%], respectively, for
UWF versus 80% [95% CI, 69e88%] and 40% [95% CI, 34%e47%], respectively, for 7-field ETDRS images). Par-
ticipants preferred ophthalmologists’ assessments; in their absence, they preferred immediate feedback by graders,
maintaining periodic ophthalmologist evaluations.When comparedwith the current standard of care, the new pathway
could save £1390 per 100 DME visits and between £461 and £1189 per 100 PDR visits.
Conclusions: The new pathway has acceptable sensitivity and would release resources. Users’ suggestions
should guide implementation. Ophthalmology 2021;128:561-573 ª 2020 by the American Academy of Ophthal-
mology. This is an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Supplemental material available at www.aaojournal.org.
See Commentary on page 574.Diabetic macular edema (DME) and proliferative diabetic
retinopathy (PDR) are the major sight-threatening compli-
cations of diabetic retinopathy that, in its turn, is the most
common microvascular complication of diabetes.1 Diabetic
macular edema and PDR are leading causes of sight
impairment and blindness worldwide.2e4ª 2020 by the American Academy of Ophthalmology
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/). Published by Elsevier Inc.Treatment for DME includes macular laser therapy,
intravitreal antievascular endothelial growth factor (VEGF)
therapies, and intravitreal steroids.5e14 Macular laser treat-
ment is delivered in a single session; retreatments may be
required and, if so, usually are administered at 3- to 4-month
intervals. Antievascular endothelial growth factor agents561https://doi.org/10.1016/j.ophtha.2020.10.030
ISSN 0161-6420/20
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great majority of patients, this is not achieved during the
first year of treatment.15 As soon as DME has resolved,
patients are followed up every 3 to 4 months after macular
laser therapy; after anti-VEGF therapy, patients initially
are followed up monthly and every 1 to 4 months there-
after.16,17 Intravitreal steroids are administered at less
frequent intervals than anti-VEGF agents, but patients
receiving them still require close follow-up because they can
lead to an increase in intraocular pressure.10 Independently
of the treatment received, follow-up continues for the rest
of the patient’s life because DME may recur and further
treatment may be required to prevent sight loss.
Laser panretinal photocoagulation (PRP) remains the
mainstay therapy for PDR.18 Laser PRP most often is
completed in 2 sessions. Recent trials have shown anti-
VEGF agents to be noninferior to PRP for the treatment
of PDR.19,20 However, anti-VEGF agents do not seem to be
cost effective when compared with laser therapy, except in
patients with concomitant DME.21 As soon as regression of
PDR is noted, patients are followed up every 6 to 12 months
for life because PDR also may recur.16
At follow-up appointments, ophthalmologists with
expertise in retinal diseases examine the retina by slit-lamp
biomicroscopy and determine whether recurrence of DME,
PDR, or both is present. Spectral-domain (SD) OCT is used
routinely to aid the diagnosis of DME. Although the prev-
alence of DME and PDR is not very high (approximately
7% of all people with diabetes),22,23 given the very high
prevalence of diabetes in the population,24,25 with
approximately 463 million adults worldwide living with
diabetes, and the requirement for patients to be reviewed
frequently and for life, as underlined above, diabetic eye
disease is posing major problems of capacity in
ophthalmic clinics in many countries, especially because
of the shortage of ophthalmologists.26 As a result,
patients’ appointments often are delayed, and treatments
are not administered in a timely fashion. Delays in follow-
up appointments in secondary care have been shown to
lead to sight loss and even blindness in people with diabetic
retinopathy.27 The challenge that diabetes poses to health
care systems in developed and especially developing
countries was highlighted recently.16 Retinal clinics are
stretched further because anti-VEGF agents are used also
to treat other diseases, including age-related macular
degeneration and retinal vein occlusion. Cancellations of all
routine appointments worldwide during the ongoing coro-
navirus disease 2019 pandemic have exacerbated this
problem to unprecedented levels. Thus, it is imperative that
new ways to increase efficiency and capacity of ophthalmic
clinics are identified and, if safe and acceptable, are
implemented.
The Effectiveness of Multimodal Imaging for the Eval-
uation of Retinal Oedema and New Vessels in Diabetic
Retinopathy (EMERALD) study was conceived with the
above purpose. It tested whether patients with DME, PDR,
or both previously treated successfully (i.e., DME cleared
and PDR became inactive) could be followed up through a
new care pathway involving multimodal retinal imaging
assessed by trained nonmedical staff (ophthalmic graders).562Diagnostic accuracy, cost consequences, and acceptability
of this new pathway to patients and health care professionals
were evaluated against the current standard of care (face-to-
face evaluation of patients by ophthalmologists).Methods
Ethical approval was obtained from the Office for Research Ethics
Committees Northern Ireland (ORECNI). The Belfast Health and
Social Care Trust acted as sponsor and approved the study, and the
study was conducted in accordance with the ethical principles of
the Declaration of Helsinki. The EMERALD study was funded by
the Health Technology Assessment of the National Institute for
Health Research in the United Kingdom (identifier, 13/142/04).
Patient and Public Involvement
At study conception, a patient and public involvement (PPI) group
was established, with the help of Diabetes UK, Northern Ireland.
Meetings and discussions between EMERALD study researchers
and the EMERALD PPI group took place early on, at the planning
stages of the project, to confirm that the research question was
important and that the tests proposed were adequate and feasible to
patients. In addition, the PPI group provided help and input to the
elaboration of participant-related materials for the study and will
provide support with the dissemination of findings.
Study Design, Setting, Participants, and
Recruitment Period
The EMERALD study was designed as a case-referent, cross-
sectional, multicenter, diagnostic study with sampling of patients
and data collection carried out prospectively,28 providing a cost-
efficient design with low risk of bias in terms of diagnostic accu-
racy.29 The study was conducted in ophthalmic clinics of 13
National Health Service (NHS) hospitals across the United
Kingdom, with sites in England (n ¼ 11), Scotland (n ¼ 1), and
Northern Ireland (n ¼ 1). Eligible participants were adults with
diabetes (type 1 or 2) with previously successfully treated DME
or PDR in one or both eyes. Participants were considered to
have been treated successfully if, at the last visit in clinic, no
further treatment had been indicated by the treating
ophthalmologists because of lack of activity of PDR or DME.
Only participants unable to speak or understand English and
those unable to provide informed consent were excluded.
Participants were identified through clinical records, electronic
databases, or while in the clinic. At the time of enrollment, DME
and PDR could be active or inactive. An ophthalmologist
confirmed eligibility; for those willing to participate, informed
consent was obtained before enrollment. Participants were
recruited between October 26, 2017, and June 7, 2019.
Clinical Pathways Assessed and Training of
Ophthalmic Graders
New Pathway: Ophthalmic Grader Pathway. The new pathway
tested consisted of the review of SD OCT scans to detect DME and
of 7-field Early Treatment Diabetic Retinopathy Study (ETDRS)
and ultra-widefield (UWF) images to detect PDR by trained and
tested ophthalmic graders (see below). Ophthalmic graders deter-
mined whether there was active or inactive DME or PDR, or
whether they were unsure or unable to grade images, in which case
patients would be referred for an ophthalmologist assessment. If no
DME or no active PDR was present, the grader would arrange a
Lois et al  New Model of Care for DRreview appointment for the patient in the ophthalmic grader
pathway at a predetermined interval.
Standard-of-Care Pathway (Reference Standard). The
standard-of-care pathway for DME and PDR was the current
standard of care: face-to-face evaluation of patients by ophthal-
mologists using slit-lamp biomicroscopy and SD OCT scans.
Active or inactive DME or PDR were judged by ophthalmologists
based on clinical examination and, for DME, findings on SD OCT.
Enhanced Reference Standard for Proliferative Diabetic
Retinopathy. Because ophthalmologists may miss new vessels
when evaluating patients by slit-lamp biomicroscopy, the
EMERALD study included an enhanced reference standard for
PDR. This consisted of the reference standard, as above, supple-
mented by the evaluation of 7-field ETDRS and UWF images, both
reviewed by an ophthalmologist expert in diabetic retinopathy. If
active PDR was detected in 1 of these 3 evaluations (slit-lamp
biomicroscopy, 7-field ETDRS images, or UWF fundus images),
the patient was considered to have active PDR based on the
enhanced reference standard.
Images were obtained by trained ophthalmic photographers and
imaging technicians at participating sites. Seven-field ETDRS
images were obtained using standard fundus cameras available at
each participating site. The Optos system (Optos, Inc) was used to
obtain UWF images.
In the EMERALD study, all participants went through the
standard-of-care pathway (i.e., they were reviewed by an
ophthalmologist who set the reference standard). Spectra-domain
OCT scans were obtained according to the standard of care. For
the purpose of the study, 7-field ETDRS and UWF images were
obtained to detect PDR in the ophthalmic grader pathway and for
the enhanced reference standard.
Anonymized images were transferred from participating sites to a
central facility, then were assigned randomly to graders and oph-
thalmologists in the clinical sites. The EMERALD study used a
commercially available platform (Ophthalsuite; BlueWorks, Coim-
bra, Portugal) for graders to see all images on computer screens.
Selection and training of ophthalmic graders was as follows.
First, local principal investigators suggested names of individuals
at their sites with experience obtaining or grading images of pa-
tients with DME or PDR. These individuals were approached to
confirm their interest and willingness to participate in the
EMERALD study. They were asked to fill out a questionnaire
detailing their experience recognizing features of DME and PDR;
those who stated they did not have experience and those unwilling
to be part of the study were not invited to participate in the
EMERALD study.
Candidates to be ophthalmic graders then received formal
training. During training, which included a 2-day face-to-face
meeting and 2 additional half-day webinar sessions, features of
active and inactive DME and PDR were reviewed and discussed,
and extensive clinical examples were presented. A web-based
teaching module with examples of DME and PDR was provided
also, so that graders could consolidate their knowledge. Graders
received clear guidelines on when patients needed referral to
ophthalmologists. The following definitions for active and inactive
DME and PDR were given:1. Active DME was defined as DME with central retinal
thickness of more than 300 mm on SD OCT, and/or the
presence of intraretinal or subretinal fluid, or both, on SD
OCT resulting from DME. Isolated or sparse small intra-
retinal cysts were not considered DME.
2. Inactive DME was defined as no intraretinal or subretinal
fluid.3. Active PDR was defined by the presence of subhyaloid or
vitreous hemorrhage, active new vessels (new vessels with
lack of fibrosis on them), or both.
4. Inactive PDR was defined by a lack of subhyaloid or vit-
reous hemorrhage and lack of active new vessels.After training, ophthalmic graders were required to take a test
involving the reading of SD OCT, 7-field ETDRS, and UWF im-
ages with and without DME and with and without active PDR.
Those reaching a minimum of 80% of correct answers were invited
to take part in the EMERALD study. If they failed the first test,
graders could undergo further training and take a new test, but if
the 80% minimum was not attained,30 they were unable to be
graders for the EMERALD study.
Masking
Ophthalmic graders were masked to the reference standard. To
ensure this, they did not interpret images from patients recruited at
their own center and had no access to results of the reference
standard. They did not read 7-field ETDRS, UWF, and SD OCT
images of the same eye to ensure reading of one imaging tech-
nology would not influence the reading of the other. Ophthal-
mologists performing the standard-of-care evaluation (i.e., setting
the reference standard) were masked to the findings and decisions
made by ophthalmic graders (who reviewed images at a later date)
and to the enhanced reference standard.
Outcome Measures
The primary outcome measure was sensitivity of the new pathway
to detect DME and active PDR. The secondary outcome measures
included specificity, concordance, costs, acceptability of the new
pathway to patients and health care professionals, the proportion of
patients requiring subsequent assessment by ophthalmologists, the
proportion of patients unable to undergo imaging, and the pro-
portion of patients with images of inadequate quality for
interpretation.
Acceptability of the New Pathway to Patients
and Health Care Professionals
Focus group discussions were undertaken. Participants were
approached and consent was obtained from those willing to
participate in focus group discussions at the same time that they
were approached to participate in the main diagnostic accuracy
study. Ophthalmologists and ophthalmic photographers and
graders also were invited to participate in separate focus group
discussions. Detailed methodology and results of this qualitative
part of the EMERALD study will be published separately.
Sample Size and Statistical Analysis
The sample size was determined based on setting a target of the
number of people with reactivated (active) DME and PDR required
to enable sensitivity to be tested against a prespecified target level
of 80%. The required sample size was calculated using formula T1
from Obuchowski31 in Microsoft Excel (Microsoft); it was a Wald
test-based calculation. This level was considered the minimum
acceptable for the new pathway to be clinically viable. A lower
specificity was considered acceptable; a target of 65% was used to
confirm sufficiency of the sample size to assess specificity. Eighty-
nine participants with DME or PDR that had reactivated (active
DME or PDR) was sufficient to detect if the sensitivity of the new
pathway was 10% and 12% higher than the 80% minimal target set
with 80% and 90% power, respectively, at the 2-sided 5%563
Ophthalmology Volume 128, Number 4, April 2021significance level.32 Ninety-three participants whose disease did
not reactivate would enable detection of a specificity 15% higher
than the 65% target with 90% power. A 95% confidence interval
(CI) for the ophthalmic grader pathway sensitivity and specificity
would have a confidence interval (Wilson method) with a width of
10% to 20%, depending on the observed level.33 Allowing for 10%
missing or indeterminate results, 104 individuals whose disease
had reactivated and 104 whose disease had not were required
(208 each for DME and PDR), leading to a maximum of 416
participants in the study overall. Because participants could have
both DME and PDR and could contribute to both targets, the
number of participants required could be fewer than 416.
Separate analyses were planned for DME and PDR. Participants
were categorized as having active or inactive DME or PDR ac-
cording to the reference standard at the person level. Those with
previously successfully treated DME or PDR constituted eligible
participants for each analysis (DME and PDR) for the new
pathway. This person-based assessment reflects the consequences
of the clinical decision in clinical practice. The diagnostic perfor-
mance of the new pathway was quantified against the reference
standard. Reflecting how the new pathway would function in
practice, unsure, ungradable, and active classifications required
referral and examination by an ophthalmologist under the main
analyses. The impact of using 7-field ETDRS images versus UWF
images on the diagnostic performance of the new pathway was
assessed under the principal analyses for PDR using both the
reference standard and enhanced reference standard. Agreement
between PDR assessment methods was quantified.
Planned sensitivity analyses included (1) assessment of the
impact of unsure and ungradable classifications on the diagnostic
performance of the ophthalmic grader; (2) using the ophthalmol-
ogist’s decision that further treatment was required, rather than
presence of active disease; (3) detection of severe disease (central-
involving in DME or subhyaloid or vitreous hemorrhage in PDR);
(4) diagnostic performance within routine NHS clinics versus
research clinics; and (5) for PDR only, diagnostic performance of
the ophthalmic grader against the enhanced reference standard
(Table S1, available at www.aaojournal.org).
Secondary analyses included evaluation of eye-level data:
analysis of all patients (with or without DME or PDR), assessment
of the overall referral (for DME and PDR), and use of visual acuity
as a proxy to detect active disease. Additional post hoc analyses
were carried out in the PDR group only to aid the understanding of
findings of preplanned analyses (Table S1).
The main analysis and sensitivity analysis included only
eligible participants for the particular pathway (for the new DME
pathway, patients with at least 1 eye with previously successfully
treated DME; for the new PDR pathway, patients with at least 1
eye with previously successfully treated PDR). These participants
might have had an ineligible eye, but because these analyses were
based on the person level (because this is what will happen in real
life if the pathway is introduced), each of the two eyes would have
been taken into consideration for the analysis. For example, if a
participant had a right eye with previously treated and inactive
DME, this participant would have entered the DME pathway. If a
recurrence of DME were present in the right eye at the time of the
EMERALD evaluation, the patient would have been considered to
have active DME. Equally, if this same participant showed
persistence (i.e., had never been treated successfully before the
EMERALD evaluation, but showed active disease at the time of
the visit) or de novo disease (active disease at the time of the
EMERALD evaluation but never present before) in the left eye, the
participant also would have been considered to have active DME.
If this same participant did not have PDR in the right eye or left eye
before (i.e., not eligible for the PDR pathway) but, at the time of564the EMERALD study, showed de novo PDR in 1 eye, this
participant would not have been included in main or sensitivity
analyses for PDR but would have been included in the secondary
analysis. The converse also was true for the DME main and
sensitivity analyses, and correspondingly the inclusion of de novo
DME in the secondary analysis.
For all diagnostic accuracy analyses, the sensitivity, specificity,
and positive and negative likelihood ratios were calculated (with
appropriate 95% CIs using Wilson’s method and the diagt com-
mand in Stata software, respectively). The difference in sensitivity
and specificity between 7-field ETDRS and UWF images assessed
by the ophthalmic graders was compared with corresponding 95%
CIs produced using Newcombe’s method for paired data34 and
McNemar’s test for the main analysis and sensitivity analysis
1.35 All analyses were carried out using Stata software version
15 (Stata Corp) and without imputation of missing data.
Health Economic Evaluation
Resource use was captured on EMERALD case report forms at
each participant’s EMERALD clinic visit to compare costs of
delivering the standard-of-care pathway, the ophthalmic grader
pathway, and the enhanced reference standard. The cost analysis
took the perspective of the NHS and personal social services and
was estimated in United Kingdom pounds sterling using 2019
through 2020 prices. Costs included staff costs, based on the time
and staff (including grade) required to obtain best-corrected visual
acuity, SD OCT images, 7-field ETDRS images, and UWF fundus
images. Costs included time and grade of the ophthalmologist
evaluating the patient in the clinic, including undertaking slit-lamp
biomicroscopy, review of the SD OCT images to assess DME, as
well as the time invested counseling the patient. Times taken by
graders to grade SD OCT images and by graders and ophthal-
mologists (for the purpose of the enhanced reference standard) to
grade 7-field ETDRS and UWF fundus images also were obtained
and costed. Hourly wage rates for staff costs were obtained from
the Unit Costs of Health and Social Care 2019. Other costs
included the equipment required, overhead, and consumables. The
equipment costs included acquisition and maintenance costs,
considering the lifetime of the equipment and estimated throughput
per year. Data were not collected on costs to patients.
It was hypothesized that the new pathway would show similar
sensitivity as the standard-of-care pathway but at lower cost,
making the analysis a cost-consequence one, including assessment
of ophthalmologist time released by the new pathway. Diabetic
macular edema and PDR were assessed separately. Detailed
methodology and results of the health economic evaluation will be
published separately.
Statistical analysis and health economic plans were agreed upon
and made accessible on the EMERALD website (http://www.nic-
tu.hscni.net/emerald-trial/#) before commencement of data anal-
ysis. Further methodologic details of the EMERALD study can be
found in the published protocol (https://bmjopen.bmj.com/content/
9/6/e027795).36 The EMERALD study was executed and reported
following the Standards for Reporting of Diagnostic Accuracy
Studies (STARD) guidelines37 and was registered prospectively




We recruited 397 participants, of whom 272 were eligible with
DME and 281 were eligible with PDR (Fig 1; Table S2 and S3,
Lois et al  New Model of Care for DRavailable at www.aaojournal.org). Participants were recruited
consecutively, whether they had active or inactive DME or PDR
at the time of the EMERALD visit, with no case selection.34 We
had planned to continue recruitment until we had achieved the
minimum number of eligible participants for each group (104
individuals each for the active and inactive DME and PDR
groups). Because participants could contribute to both the DME
and PDR pathways, by February 8, 2019, we had recruited
enough participants for 3 groups (active DME, inactive DME,
and inactive PDR). People with previously successfully treated
and active PDR seemed to be seen in clinics less frequently, and
thus, numbers recruited in this group had not reached the
required minimum. Thus, from February 8, 2019, when we had
67 participants with active PDR (167 with inactive PDR, 141
active DME, and 107 with inactive DME, respectively), we
decided actively to recruit patients who had active PDR only and
to ask sites actively to pursue eligible participants for this group
(e.g., recruiting from casualty, where these patients initially
could seek treatment). Consecutive potentially eligible
participants with active PDR then were approached until
recruitment for this group was completed also (and surpassed,
because recruitment was not halted until all potentially eligible
participants identified and approached for the active PDR group
had been assessed). Because participants could contribute to all
other groups, as mentioned above, the number of eligible
participants in all groups increased and was higher by the end of
the study than that required based on sample size calculations.
Demographics of participants are shown in Table 1. In total, 157
of 397 patients (40%) demonstrated severe disease (central-involving
DME) in the DME group, and 132 patients were eligible for the new
pathway. In the PDR group, severe disease (PDR with preretinal or
vitreous hemorrhage) was present in 77 of 397 participants (19%),
and 75 patients were eligible for the new pathway.
All participants except 34 (9%) had all images (i.e., SD OCT, 7-
field ETDRS, and UWF images) obtained for testing the ophthalmic
grader pathway on the same day as the reference standard. The great
majority of eyes (92%e97% of eyes, depending on the imaging
technology used) could be imaged, and few images were ungradable
(1% of SD OCT images, 6% of 7-field ETDRS images, and 5% of
UWF images). Details for missing images are summarized in Table
S4 (available at www.aaojournal.org).
In the main analysis, ophthalmic graders showed sensitivity of
97% (142/147; 95% CI, 92%e99%) and specificity of 31% (35/
113; 95% CI, 23%e40%) when compared with the reference
standard to detect DME (Table 2). Similar results were found when
evaluating people with DME requiring further treatment, with
central-involving DME, and when only referral for active DME
was considered (i.e., excluding those with unsure and ungradable
results) and when patients were assessed in the NHS versus
research clinics (Table 2; Table S5, available at
www.aaojournal.org).
In the main analysis, ophthalmic graders showed lower sensi-
tivity but higher specificity to detect PDR; both were similar
(paired differences in sensitivity, e3% [95% CI, e14% to 8%; P ¼
0.55]; and specificity, 5% [95% CI, e5% to 16%; P ¼ 0.31])
whether they used 7-field ETDRS images (sensitivity, 85% [87/
102; 95% CI, 77%e91%]; specificity, 48% [77/160; 95% CI,
41%e56%]) or UWF images (sensitivity, 83% [87/105; 95% CI,
75%e89%]; specificity, 54% [86/160; 95% CI, 46%e61%;
Table 3). Results against the enhanced reference standard were
similar to those against the reference standard (for 7-field
ETDRS images: sensitivity, 82% [111/135; 95% CI, 75%e88%];
specificity, 54% [68/127; 95% CI, 45%e62%]; for UWF images:
sensitivity, 80% [110/138; 95% CI, 72%e86%]; specificity, 60%
[76/127; 95% CI, 51%e68%]). Diagnostic accuracy results weresimilar to those of the main analysis when grading patients
requiring further treatment (Table 3; Table S6, S7, and S8,
available at www.aaojournal.org). Sensitivity and specificity to
detect more severe disease (PDR with subhyaloid or vitreous
hemorrhage, or both) seemed to be slightly higher (not formally
compared) when using UWF imaging (sensitivity, 87% [62/71;
95% CI, 78%e93%]; specificity, 49% [95/193; 95% CI, 42%e
56%]) instead of 7-field ETDRS imaging (sensitivity, 80% [53/
66; 95% CI, 69%e88%]; specificity, 40% [79/196; 95% CI, 34%e
47%]). Findings were similar whether patients were assessed in the
NHS or research clinics. Sensitivity and specificity were lower
when considering only referrals for active PDR (i.e., excluding
those with unsure and ungradable results; Table 3).
Results of post hoc additional analyses for PDR, and the sec-
ondary analyses, are shown in Table 3 and Table S9 (available at
www.aaojournal.org). The additional analyses for PDR tended to
show similar results or increased specificity with reduced
sensitivity. Secondary analyses showed very high sensitivity with
low or very low specificity. No adverse events were experienced
by participants in either pathway.
Acceptability
Thirty-six participants attended focus groups organized in Northern
Ireland (n¼ 4), Scotland (n ¼ 2), and England (n ¼ 4). Participants
voiced preference for face-to-face examinations by ophthalmolo-
gists, where information about their eye condition could be
received and discussed and where they would have the opportunity
to ask questions and have anxieties assuaged. In their absence, they
wished immediate results from the grader’s assessment and
maintaining periodic evaluations by ophthalmologists, even if at
longer intervals. Participants were uncertain of professional iden-
tity, training, and performance of photographers and graders.
Graders and ophthalmologists supported the new pathway, but
graders expressed caution about their ability to answer questions
from patients unrelated to the activity of their disease.
Cost-Consequence Analysis
For DME, the cost difference (savings) for the grader’s pathway is
£1390 per 100 follow-up visits. For PDR, the cost difference
(savings) for the grader’s pathway is £461 for 7-field ETDRS
images and £1889 for UWF images per 100 follow-up visits. The
main driver of the difference in costs of imaging methods for PDR
was the time to obtain and read images (Table S10, available at
www.aaojournal.org). Costs for the grader pathway took into
account the specificity of the pathway (i.e., in each 100 patients,
a proportion of false-positive results still need to be referred to
an ophthalmologist, with the reference standard cost for ophthal-
mologist follow-up applied).Discussion
The new ophthalmic grader pathway showed high sensi-
tivity to detect DME of more than 90% in all analyses,
suggesting that it would be safe to implement in clinical
practice. The pathway showed lower sensitivity to detect
PDR, albeit more than the 80% level set. Importantly, the
sensitivity of the ophthalmic grader pathway to detect high-
risk PDR, with preretinal or vitreous hemorrhage, or both,
was higher (87%) when using UWF fundus images. It
should be highlighted that the risk and consequences of a
recurrence of PDR in eyes previously treated with PRP565
Figure 1. Effectiveness of Multimodal Imaging for the Evaluation of Retinal Oedema and New Vessels in Diabetic Retinopathy flow diagram. DME ¼
diabetic macular edema; O-FTF¼ Ophthalmologist face-to-face clinical evaluation using slit-lamp biomicroscopy; PDR ¼ proliferative diabetic retinopathy;
SD ¼ spectral-domain.
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disease were to occur in treatment-naive eyes. If a vitreous
hemorrhage were to develop, patients would experience
floaters and could be instructed to contact ophthalmic clinics
immediately for timely evaluation. In most instances, the
course of action is observation until the hemorrhage clears,
and then further PRP treatment if required. With this in
mind, the ophthalmic grader pathway for PDR is considered
adequate and justifiable, especially in areas and at times of
high demand for services that prevent people with severe
eye diseases from accessing timely care. Given that UWF
images showed higher sensitivity to detect high-risk PDR
and were less costly than 7-field ETDRS images, they may
be preferred.
The specificity of the new pathway to detect DME (31%)
and PDR (54%e60%) was not high. The lower the speci-
ficity, the more patients with false-positive results who have
to be seen by the ophthalmologist. However, even a poor
specificity could provide useful savings in ophthalmologist566time. In the EMERALD study, images were evaluated
without any information about patients (i.e., masked to any
clinical data, including previous images). Although this was
a strength in scientific design, it is likely that if clinical in-
formation (e.g., location of previously identified new ves-
sels) and previous images (e.g., SD OCT scans of previously
treated DME or images of new vessels after PRP treatment)
were to be available, the sensitivity and specificity of the
new pathway would have been higher. Indeed, if the new
pathway is implemented in clinical practice, previous clin-
ical information and images could be available to
ophthalmic graders.
The new ophthalmic grader pathway, if implemented
appropriately, would help health services to increase ca-
pacity, would reduce waiting times for patients to be seen in
clinics, and subsequently, would save sight. For example,
the pathway could be implemented as a 1-stop clinic, with
images and image review being carried out at the same
session and ophthalmic graders providing the results to
Table 1. Demographic Characteristics of Effectiveness of Multimodal Imaging for the Evaluation of Retinal Oedema and New Vessels in
Diabetic Retinopathy Study Participants
Patients with Diabetic
Macular
Edema (n [ 317)
Eligible for Diabetic
Macular
Edema in the New












Male 205 (65) 175 (64) 187 (65) 185 (66) 257 (65)
Female 112 (35) 97 (36) 100 (35) 96 (34) 140 (35)
Age (yrs)
18e59 135 (43) 113 (42) 151 (53) 148 (53) 188 (47)
60 and older 182 (57) 159 (58) 136 (47) 133 (47) 209 (53)
Ethnic origin
White 274 (86) 240 (88) 240 (84) 234 (83) 340 (86)
Black 20 (6) 17 (6) 19 (7) 19 (7) 26 (7)
Asian 16 (5) 11 (4) 20 (7) 20 (7) 22 (7)
Middle
Eastern
3 (1) 1 (<1) 5 (2) 5 (2) 5 (1)
Other 4 (1) 3 (1) 3 (1) 3 (1) 4 (1)
Data are no. (%).
Lois et al  New Model of Care for DRpatients immediately. If ophthalmologists were to be
running parallel clinics, they could provide advice to
graders, if needed, in questionable cases, increasing the ef-
ficiency of the service and reducing the number of patients
who would need to return for a further ophthalmologist
assessment. If planned adequately, it may even be possible
to administer treatments to active patients requiring them at
the same visit (e.g., after these clinics have been running for
some time, it would be possible to determine the average
number of patients requiring input from the ophthalmologist
as well as those requiring treatment and to plan accord-
ingly). Patients with previously successfully treated and
stable disease (DME, PDR, or both) could be preselected by
ophthalmologists to go into the ophthalmic grader pathway.
Based on the EMERALD study, patients could be moved to
the grader’s pathway as soon as further treatment for DME
or PDR is not indicated. Alternatively, ophthalmologists
may decide, for example, to refer to the grader pathway
those patients with PDR with adequate laser PRP whose
disease has remained stable for a number of months already
(e.g., 3e4 months), patients with DME who received focal
laser treatment and in whom DME has resolved, and pa-
tients with DME who received anti-VEGF therapy and who
remained free of fluid for a certain period (e.g., 2e3
consecutive visits). Based on the focus group work con-
ducted in the EMERALD study and to ensure acceptability
by patients of the new pathway, it would be important that,
from time to time, patients whose disease remains inactive
are still seen by ophthalmologists.
No clear view exists on what should be the minimal
sensitivity and specificity acceptable for diagnostic or sur-
veillance pathways. Figures of 80% for sensitivity and 95%
for specificity have been quoted in many articles on
screening for diabetic retinopathy. These figures seem to
have originated from a 1997 British Diabetic Association
document, based on a consensus conference in 1995
(however, this document is no longer accessible).Surveillance of previously treated patients, in any case, is a
rather different scenario and would pose different, known,
risks than DR screening, in which those naïve to treatment
are followed up at less frequent intervals.
In the future, it may be possible to use automatic image
analysis, including artificial intelligence, to determine
presence of active DME or PDR on fundus and SD OCT
images. Recent studies demonstrated excellent sensitivity
and specificity of artificial intelligence methods to determine
presence of referable diabetic retinopathy (defined as pres-
ence of moderate and higher stages of nonproliferative
diabetic retinopathy, PDR, or DME) in fundus images when
compared with evaluation by retinal specialists.38,39 Indeed,
an artificial intelligence system (IDx-DR; IDx Technologies,
Inc., Coralville, IA) has been developed and approved by
the Food and Drug Administration for the automated
diagnosis of diabetic retinopathy. However, studies on
which this program was developed included mostly
treatment-naive patients, and thus, it remains to be eluci-
dated if its diagnostic performance would be the same in the
more complex group of previously treated patients who will
have demonstrated alterations in retinal structure even when
active disease is not present.
The concept of what has been widely called virtual
clinics (evaluation of patients by looking at their images
rather than through a face-to-face consultation in clinic) is
not new. Published studies presented the experience of
several groups using this form of evaluation for people with
age-related macular degeneration40 and other medical retinal
diseases, including diabetic retinopathy41e44 and glau-
coma.45 These studies showed that implementation of
virtual clinics was feasible and reduced patients’ time in
clinic, improving patients’ journeys, and seemed to
increase the efficiency of the service. However, most
studies were based on the assessment of images by
ophthalmologists, rather than allied nonmedical staff,
included newly referred patients, rather than previously567
Table 2. Diagnostic Performance of the Ophthalmic Grader Pathway for the Diagnosis of Diabetic Macular Edema
Positive Test Results Reference Standard Diagnostic Parameter No./ Total No. Estimate (95% Confidence Interval)
Main Ophthalmic graders
referral* for DME







the addition of SD
OCT scans to assess
active DME in
either eye
Sensitivity (%) 142/147 97% (92%e99%)
Specificity (%) 35/113 31% (23%e40%)
Positive likelihood ratio d 1.40 (1.23e1.59)
Negative likelihood ratio d 0.11 (0.04e0.27)
SENA1 Ophthalmic graders
identified active







the addition of SD
OCT scans to assess
active DME in
either eye
Sensitivity (%) 139/146 95% (90%e98%)
Specificity (%) 43/113 38% (30%e47%)
Positive likelihood ratio d 1.54 (1.32e1$78)
Negative likelihood ratio d 0.13 (0.06e0.27)
SENA2 Ophthalmic graders
referral for DME







the addition of SD




Sensitivity (%) 81/85 95% (89%e98%)
Specificity (%) 36/175 21% (15%e27%)
Positive likelihood ratio d 1.20 (1.10e1.31)











the addition of SD




Sensitivity (%) 121/129 94% (88%e97%)
Specificity (%) 72/128 56% (48%e65%)
Positive likelihood ratio d 2.14 (1.75e2.62)
Negative likelihood ratio d 0.11 (0.06e0.22)
SENA6 Ophthalmic graders
referral for DME








the addition of SD




Sensitivity (%) 81/85 95% (89%e98%)
Specificity (%) 26/65 40% (29%e52%)
Positive likelihood ratio d 1.59 (1.30e1.95)
Negative likelihood ratio d 0.12 (0.04e0.32)
DME ¼ diabetic macular edema; SD ¼ spectral-domain; SENA ¼ sensitivity analysis; d ¼ not available.
*Grader referral for DME: active þ unsure þ ungradable.
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comers. Very few studies evaluated the acceptability of
virtual clinics to patients and health care professionals; these
used questionnaires44,46 and had low ascertainment (46%e
61%).44
The EMERALD findings may be of greatest relevance
to countries with tax-funded health care systems, those
having difficulties coping with health care demands,
especially because of the shortage of ophthalmologists,
and in particular low- and middle-income countries and
rural and underserved populations, interested in identi-
fying more efficient and less costly health care strategies.568The EMERALD study also could serve as an example of
using allied health care professionals in other areas of
health care in ophthalmology and even outside this
specialty.
Strengths of the EMERALD study include its multi-
center nature, strong methodology, adequate power and
recruitment, and lack of patient selection, making results
more generalizable and applicable to routine care. Ca-
veats include the fact that images of the iris and anterior
chamber angle were not obtained for the evaluation of
people with PDR. Although it would be very rare that
new vessels would develop in these structures in eyes
Table 3. Diagnostic Performance of the Ophthalmic Grader Pathway for the Diagnosis of Proliferative Diabetic Retinopathy
Results Reference Standard Diagnostic Parameter No./Total No. Estimate (95% Confidence Interval)
Main Ophthalmic graders referral* for PDR based on
ultra-widefield fundus images
Ophthalmologist face-to-face clinical evaluation
using slit-lamp biomicroscopy to assess active
PDR in either eye
Sensitivity (%) 87/105 83% (75%e89%)
Specificity (%) 86/160 54% (46%e61%)
Positive likelihood ratio d 1.79 (1.48e2.16)
Negative likelihood ratio d 0.32 (0.20e0.50)
Ophthalmic graders referral for PDR based on 7-field
ETDRS fundus images
Ophthalmologist face-to-face clinical evaluation
using slit-lamp biomicroscopy to assess active
PDR in either eye
Sensitivity (%) 87/102 85% (77%e91%)
Specificity (%) 77/160 48% (41%e56%)
Positive likelihood ratio d 1.64 (1.39e1.95)
Negative likelihood ratio d 0.31 (0.19e0.50)
SENA1 Ophthalmic graders identified active PDR based on
ultra-widefield fundus images
Ophthalmologist face-to-face clinical evaluation
using slit-lamp biomicroscopy to assess active
PDR in either eye
Sensitivity (%) 66/105 63% (53%e71%)
Specificity (%) 116/159 73% (66%e79%)
Positive likelihood ratio d 2.32 (1.73e3.12)
Negative likelihood ratio d 0.51 (0.39e0.66)
Ophthalmic graders identified active PDR based on
7-field ETDRS fundus images
Ophthalmologist face-to-face clinical evaluation
using slit-lamp biomicroscopy to assess active
PDR in either eye
Sensitivity (%) 70/99 71% (61%e79%)
Specificity (%) 110/158 70% (62%e76%)
Positive likelihood ratio d 2.33 (1.78e3.04)
Negative likelihood ratio d 0.42 (0.30e0.58)
Additional 1 Ophthalmologist assessment identified active PDR
based on ultra-widefield fundus images
Ophthalmologist face-to-face clinical evaluation
using slit-lamp biomicroscopy to assess active
PDR in either eye
Sensitivity (%) 74/103 72% (62%e80%)
Specificity (%) 137/159 86% (80%e91%)
Positive likelihood ratio d 5.19 (3.46e7.80)
Negative likelihood ratio d 0.33 (0.24e0.45)
Ophthalmologist assessment identified active PDR
based on 7-field ETDRS fundus images
Ophthalmologist face-to-face clinical evaluation
using slit-lamp biomicroscopy to assess active
PDR in either eye
Sensitivity (%) 65/98 66% (57%e75%)
Specificity (%) 134/154 87% (81%e91%)
Positive likelihood ratio d 5.11 (3.31e7.87)
Negative likelihood ratio d 0.39 (0.29e0.51)
SENA2 Ophthalmic graders referral for PDR based on ultra-
widefield fundus images
Ophthalmologist face-to-face clinical evaluation
using slit-lamp biomicroscopy to assess active
PDR in either eye requiring treatment
Sensitivity (%) 77/90 86% (77%e91%)
Specificity (%) 91/175 52% (45%e59%)
Positive likelihood ratio d 1.78 (1.49e2.13)
Negative likelihood ratio d 0.28 (0.16e0.47)
Ophthalmic graders referral for PDR based on 7-field
ETDRS fundus images
Ophthalmologist face-to-face clinical evaluation
using slit-lamp biomicroscopy to assess active
PDR in either eye requiring treatment
Sensitivity (%) 74/84 88% (79%e93%)
Specificity (%) 82/178 46% (39%e53%)
Positive likelihood ratio d 1.63 (1.40e1.91)
Negative likelihood ratio d 0.26 (0.14e0.47)
SENA4 Ophthalmic graders referral for PDR based on ultra-
widefield fundus images
Ophthalmologist face-to-face clinical evaluation
using slit-lamp biomicroscopy to assess active
PDR with preretinal or vitreous hemorrhage
in either eye
Sensitivity (%) 62/71 87% (78%e93%)
Specificity (%) 95/193 49% (42%e56%)
Positive likelihood ratio d 1.71 (1.45e2.02)
Negative likelihood ratio d 0.26 (0.14e0.48)
Ophthalmic graders referral for PDR based on 7-field
ETDRS fundus images
Ophthalmologist face-to-face clinical evaluation
using slit-lamp biomicroscopy to assess active
PDR with preretinal or vitreous hemorrhage
in either eye
Sensitivity (%) 53/66 80% (69%e88%)
Specificity (%) 79/196 40% (34%e47%)
Positive likelihood ratio d 1.35 (1.14e1.59)


















Results Reference Standard Diagnostic Parameter No./Total No. Estimate (95% Confidence Interval)
Additional 2 Ophthalmologist assessment identified active PDR
based on ultra-widefield fundus images
Ophthalmologist face-to-face clinical evaluation
using slit-lamp biomicroscopy to assess active
PDR with preretinal or vitreous hemorrhage
in either eye
Sensitivity (%) 57/70 81% (71%e89%)
Specificity (%) 153/192 80% (73%e85%)
Positive likelihood ratio d 4.01 (2.96e5.42)
Negative likelihood ratio d 0.23 (0.14e0.38)
Ophthalmologist assessment identified active PDR
based on 7-field ETDRS fundus images
Ophthalmologist face-to-face clinical evaluation
using slit-lamp biomicroscopy to assess active
PDR with preretinal or vitreous hemorrhage
in either eye
Sensitivity (%) 42/64 66% (53%e76%)
Specificity (%) 145/188 77% (71%e83%)
Positive likelihood ratio d 2.87 (2.09e3.94)
Negative likelihood ratio d 0.45 (0.31e0.63)
SENA5 Ophthalmic graders referral for PDR based on ultra-
widefield fundus images
Enhanced reference standard Sensitivity (%) 110/138 80% (72%e86%)
Specificity (%) 76/127 60% (51%e68%)
Positive likelihood ratio d 1.98 (1.58e2.49)
Negative likelihood ratio d 0.34 (0.24e0.49)
Ophthalmic graders referral for PDR based on 7-field
ETDRS fundus images
Enhanced reference standard Sensitivity (%) 111/135 82% (75%e88%)
Specificity (%) 68/127 54% (45%e62%)
Positive likelihood ratio d 1.77 (1.45e2.17)
Negative likelihood ratio d 0.33 (0.22e0.49)
Additional 3 Ophthalmic graders referral for PDR based on ultra-
widefield fundus images
Ophthalmologist face-to-face clinical evaluation
using slit-lamp biomicroscopy to assess active
PDR in either eye plus ophthalmologist
assessment identified active PDR in either eye
based on ultra-widefield fundus images
Sensitivity (%) 101/125 81% (73%e87%)
Specificity (%) 80/140 57% (49%e65%)
Positive likelihood ratio d 1.89 (1.53e2.32)
Negative likelihood ratio d 0.34 (0.23e0.49)
Ophthalmic graders referral for PDR based on 7-field
ETDRS fundus images
Ophthalmologist face-to-face clinical evaluation
using slit-lamp biomicroscopy to assess active
PDR in either eye plus ophthalmologist
assessment identified active PDR in either eye
based on 7-field ETDRS fundus images
Sensitivity (%) 103/122 84% (77%e90%)
Specificity (%) 73/140 52% (44%e60%)
Positive likelihood ratio d 1.76 (1.46e2.13)
Negative likelihood ratio d 0.30 (0.19e0.46)
SENA6 Ophthalmic graders referral for PDR based on ultra-
widefield fundus images in routine clinic
Ophthalmologist face-to-face clinical evaluation
using slit-lamp biomicroscopy to assess active
PDR in either eye in routine clinic
Sensitivity (%) 63/77 82% (72%e89%)
Specificity (%) 47/92 51% (41%e61%)
Positive likelihood ratio d 1.67 (1.32e2.11)
Negative likelihood ratio d 0.36 (0.21e0.60)
Ophthalmic graders referral for PDR based on 7-field
ETDRS fundus images in routine clinic
Ophthalmologist face-to-face clinical evaluation
using slit-lamp biomicroscopy to assess active
PDR in either eye in routine clinic
Sensitivity (%) 60/74 81% (71%e88%)
Specificity (%) 41/91 45% (35%e55%)
Positive likelihood ratio d 1.48 (1.19e1.83)
Negative likelihood ratio d 0.42 (0.25e0.71)
ETDRS ¼ Early treatment diabetic retinopathy study; PDR ¼ proliferative diabetic retinopathy; SENA ¼ sensitivity analysis; d ¼ not available.















Lois et al  New Model of Care for DRpreviously treated with laser PRP with no concomitant
active new vessels elsewhere (NVE) or new vessels in
the disc (NVD), if present, they would be missed.
Additionally, fluorescein angiography was not under-
taken as part of the study to determine activity of PDR.
It would be essential, if the new pathway is imple-
mented, that recommendations from the focus group
discussions were to be followed to ensure its accept-
ability to users.Acknowledgments
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